Results 151 to 160 of about 374,365 (198)

Effect of depot medroxyprogesterone acetate on postpartum depression

Contraception, 2010
Depot medroxyprogesterone acetate (DMPA) is commonly prescribed to women immediately postpartum due to its efficacy, convenience and lack of estrogen. It is unclear whether administering a progestin injection can affect the course of postpartum depression (PPD), which some suspect to be influenced by hormonal changes.
Rita, Tsai, Jonathan, Schaffir
openaire   +2 more sources

Use of depot medroxyprogesterone acetate in Thai adolescents

Contraception, 2000
Depot medroxyprogesterone acetate (DMPA) has been available for several decades in many parts of the world including Thailand, but few data have been reported concerning adolescents. The aim of the study was to determine the use of DMPA for contraceptive use among Thai adolescents. A cross-sectional study has been designed.
P, Chotnopparatpattara, S, Taneepanichskul   +1 more
openaire   +2 more sources

Toxicology of depot medroxyprogesterone acetate

Contraception, 1994
Depo-Provera (depot-medroxyprogesterone acetate or DMPA), administered either subcutaneously or intramuscularly, has undergone a thorough toxicological evaluation in a number of animal species. DMPA has been tested in short- and long-term toxicity studies in rodents, rabbits, and monkeys.
openaire   +2 more sources

Bone mineral density and depot medroxyprogesterone acetate

Contraception, 2006
Depot medroxyprogesterone acetate (DMPA) suppresses pituitary gonadotrophin output, thus, suppressing ovulation. Estrogen production from the ovary is also strongly inhibited, and the resulting estrogen deficiency has a detrimental impact on bone.
Paola, Albertazzi, Mirella, Bottazzi, Susan A, Steel   +2 more
openaire   +2 more sources

Pharmacist-administered depot medroxyprogesterone acetate

Contraception, 2006
Continuation rates for women using depot medroxyprogesterone acetate (DMPA) for contraception in the United States are very low. Compliance/continuation rates at 3 months range from 57% to 71% with usual care and follow-up. At 6 months the range decreases to between 35% and 63%. The continuation rate at 1 year ranges from 23% to 45%.
openaire   +2 more sources

Urinary tract infection in the users of depot‐medroxyprogesterone acetate

Acta Obstetricia et Gynecologica Scandinavica, 2004
Background.  The effects of progesterone on muscle tone, peristalsis of the ureter and also urinary vasculature may cause urinary tract infection (UTI) in women who use depot‐medroxyprogesterone acetate (DMPA) for contraception.Methods.  In a cohort study, 200 women who chose DMPA for contraception were compared with 200 women who used the withdrawal ...
Saeideh, Ziaei, Mojgane, Ninavaei, Soghrate, Faghihzadeh   +2 more
openaire   +2 more sources

Depot Medroxyprogesterone Acetate and Adolescents

Clinical Journal for Nurse Practitioners in Women's Health
Depot medroxyprogesterone acetate (DMPA) is an effective method of contraception that may be underutilized due to lack of information or access. This article updates clinicians on current evidence about the safety and potential side effects of DMPA.
Eva Fried, Mandi Lew, Maria Mock
openaire   +1 more source

Reasons for discontinuation of depot medroxyprogesterone acetate

International Congress Series, 2004
Introduction: Approximately 16 million women worldwide use injectable contraceptive to regulate their fertility, 13 million women use depot medroxyprogesterone acetate (DMPA). Since 1996, DMPA has been used by several thousands of women in Iran. DMPA have some benefits such as highly efficacious in preventing pregnancy, increase hemoglobin levels, easy
Eftekharalsadat Hajikazemi, Soghra Nikpour, Hamid Haghani   +2 more
openaire   +1 more source

Breast cancer and depot-medroxyprogesterone acetate: A review

Contraception, 1994
Depot-medroxyprogesterone acetate (DMPA) has been used world-wide since 1964 as a contraceptive in spite of the fact that it was only in 1992 licensed for contraceptive use in the USA due to concern about a possible breast cancer risk. Two recent studies have considered DMPA use and risk of breast cancer and these and earlier studies are reviewed here.
openaire   +2 more sources

Depot Medroxyprogesterone Acetate in Teens: A Risk for Bone Health?

Pediatrics, 2000
We believe it would be premature and irresponsible to suspend all use of DMPA in adolescents while we wait for these data. To remove this effective and easily administered contraceptive method would likely result in more unwanted pregnancies. The impact of teen pregnancy on the growing skeleton may also take its toll on peak bone mass and the ...
L K, Bachrach, T, Cundy, S M, Ott
openaire   +2 more sources